Relevant news and research

**18C.3 Health risks of heated tobacco products**

_Last updated July 2019_

**Research:**


Haziza, C, de La Bourdonnaye, G, Donelli, A, Poux, V, Skiada, D, Weitkunat, R et al. Reduction In Exposure To Selected Harmful And Potentially Harmful Constituents Approaching Those Observed Upon Smoking Abstinence In Smokers Switching To The Menthol Tobacco Heating System 2.2 For
Tobacco in Australia
Facts & Issues


Tobacco in Australia
Facts & Issues


Tobacco in Australia
Facts & Issues


Glantz, SA. PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes. Tob Control, Aug 2018. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30131374


Jaccard, G, Kondylis, A, Gunduz, I, Pijnenburg, J, Belushkin, M. Investigation and comparison of the transfer of TSNA from tobacco to cigarette mainstream smoke and to the aerosol of a heated
Tobacco in Australia
Facts & Issues


tobaccoinaustralia.org.au
Tobacco in Australia
Facts & Issues


Tobacco in Australia
Facts & Issues


Lempert, Lauren K, Popova, Lucy, Halpern-Felsher, Bonnie, McKelvey, Karma, Kim, Minji, Chaffee, Benjamin, Ling, Pamela, Glantz, S. Because PMI has not demonstrated that IQOS is associated with lower risks, FDA should not permit modified exposure claims, because such claims are likely to be misunderstood as modified risk claims. UCSF Center for Tobacco Control, Research and Education, Dec 2017. Available from: https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Modified%20exposure%20claim%20misleading_Dec11-final.pdf


Halpern-Felsher, Bonnie, McKelvey, Karma, Popova, Lucy, Kim, Minji, Chaffee, Benjamin, Vijayaraghavan, Maya, Ling, Pamela, Lempert, Lauren K, Glantz, S. The evidence cited in PMI’s MRTP Application indicates that the proposed labeling and warnings for IQOS will mislead consumers, particularly youth, about the product. UCSF Center for Tobacco Control, Research and Education, Dec 2017. Available from: https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/iQOS%20MRTP%20Warnings_Dec%2008-final.pdf


Tobacco in Australia
Facts & Issues


News reports:


Gale, Nathan, McEwan, Mike, Eldridge, Alison C., Fearon, Ian M., Sherwood, Neil, Bowen, Edward, Mc Dermott, Simon, Holmes, Emma, Hedge, Andrew, Hossack, Stuart, Wakenshaw, Louise, Glew, James, Camacho, Oscar M., Errington, Graham, McAughey, John, Murphy, James, Liu, Chuan, Proctor, Christopher J. Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese
Tobacco in Australia
Facts & Issues


Tobacco in Australia
Facts & Issues


Tobacco in Australia
Facts & Issues


St. Helen, Gideon, Jacob, Peyton, Nardone, Natalie and Benowitz, Neal L. Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical studies to describe exposure to toxicants during dual use with other tobacco products, FDA must deny PMI’s application. University of California San Francisco, 2017. Nov 29, 2017. Available from: https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Gideon-ClinPharm_Comments%20on%20aerosol%20and%20exposure%20IQOS%2011292017-FINAL.pdf


